Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 200, С. 104407 - 104407
Опубликована: Июнь 2, 2024
Язык: Английский
Biomolecules, Год журнала: 2024, Номер 14(8), С. 908 - 908
Опубликована: Июль 25, 2024
Post-translational modifications (PTMs) influence protein functionality by modulating stability, localization, and interactions with other molecules, thereby controlling various cellular processes. Common PTMs include phosphorylation, acetylation, ubiquitination, glycosylation, SUMOylation, methylation, sulfation, nitrosylation. Among these modifications, O-GlcNAcylation has been shown to play a critical role in cancer development progression, especially hepatocellular carcinoma (HCC). This review outlines the of progression HCC. Moreover, we delve into underlying mechanisms HCC highlight compounds that target O-GlcNAc transferase (OGT) O-GlcNAcase (OGA) improve treatment outcomes. Understanding will offer insights potential therapeutic strategies targeting OGT OGA, which could for patients
Язык: Английский
Процитировано
4
Frontiers in Immunology, Год журнала: 2025, Номер 16
Опубликована: Янв. 31, 2025
Primary central nervous system germ cell tumors (CNS GCTs) are rare intracranial malignancies, and their tumor microenvironment plays a crucial role in initiation progression. However, the specific characteristics of immune clinical significance remain poorly understood. This study included 93 paraffin-embedded tissue samples from 90 patients diagnosed with CNS GCTs. Immunohistochemistry immunofluorescence staining were used to assess infiltration patterns T subsets (CD3+, CD4+, CD8+, Foxp3+) expression levels checkpoints (CTLA-4, PD-1, PD-L1). Additionally, explored relationship between these features patient's prognosis. The revealed that germinomas exhibited significantly higher CD4+ Foxp3+ cells compared non-germinomatous GCTs (NGGCTs). CTLA-4 was detected 58.06% cases, while PD-1 PD-L1 expressed over 90%, elevated NGGCTs. positively correlated checkpoint expression, particularly germinomas. results also highlighted strong immunosuppressive nature GCTs' microenvironment. Furthermore, closely associated Notably, identified as an independent prognostic factor for progression-free survival (PFS) recurrence-free (RFS). Our distinct significant GCTs, revealing highly heterogeneous predictor, offering foundation enhancing risk stratification GCT patients. These findings support potential future applications inhibitors, such monoclonal antibodies.
Язык: Английский
Процитировано
0
European Journal of Pharmacology, Год журнала: 2025, Номер unknown, С. 177554 - 177554
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
0
Clinica Chimica Acta, Год журнала: 2025, Номер 573, С. 120293 - 120293
Опубликована: Апрель 10, 2025
Язык: Английский
Процитировано
0
World Journal of Gastrointestinal Oncology, Год журнала: 2025, Номер 17(5)
Опубликована: Май 15, 2025
One of the main causes cancer-related morbidity and mortality globally is hepatocellular carcinoma (HCC). At every stage disease, HCC may now be treated using a variety therapy techniques. Nevertheless, despite abundance effective therapeutic choices, prognosis for patients with still typically dismal. Prognostic indicators are crucial when assessing tracking tumor metastases or recurrence. There many prognostic markers in HCC. We mainly focused on newly reported such as MEX3A, apolipoprotein B, alpha-fetoprotein, circulating cells, SAMD13, Agrin, Glypican-3 pathogenesis Further, we highlighted how these correlated to clinical parameters node metastasis, diameter, differentiation, hepatocirrhosis, vascular invasion, others Therefore, identifying specific biomarkers helps provide great opportunity improve targets.
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(10), С. 4863 - 4863
Опубликована: Май 19, 2025
Alpha-fetoprotein (AFP) is a well-known biomarker for liver cancer, and its clinical utility widely recognized. Recent studies have revealed that AFP plays multifaceted role in various malignant tumors, including cancer. This suggests not merely but also contributes significantly to the complex process of tumor formation, emphasizing importance targeting therapeutic approaches. Consequently, innovative research development are essential overcome current limitations AFP-targeted therapies, enhance treatment efficacy, minimize side effects. review explores cancer progression, highlights biological functions related pathways, discusses implications therapies. Ongoing on will contribute our understanding mechanisms aid developing effective safe treatments. Ultimately, advancements approaches expected play crucial future management.
Язык: Английский
Процитировано
0
Cureus, Год журнала: 2024, Номер unknown
Опубликована: Окт. 23, 2024
Liver cancer, particularly hepatocellular carcinoma (HCC), poses a significant global health challenge due to its high mortality rate. Hepatocellular and intrahepatic cholangiocarcinoma (ICC) are the two main types of primary liver cancer (PLC), each with own set complexities. Secondary or metastatic is more common than PLC. It frequently observed in malignancies such as colorectal, pancreatic, melanoma, lung, breast cancer. often diagnosed at an advanced stage, making it difficult treat. This highlights need for focused research on early detection effective treatment strategies. review explores epidemiology, risk factors, diagnostic techniques HCC. The development HCC involves various including chronic diseases, hepatitis B C infections, alcohol consumption, obesity, smoking, genetic predispositions. Various invasive non-invasive techniques, biopsy, liquid imaging modalities like ultrasonography, computed tomography scans (CT scans), magnetic resonance (MRI), positron emission (PET) scans, utilized monitoring. Advances technology biomarker have led accurate sensitive methods detection. We also reviewed emerging next-generation sequencing, metabolomics, epigenetic biomarkers, microbiome analysis, which show great potential advancing diagnosis personalized literature provides insights into current state promising future advancements. Ongoing innovation these areas essential improving reducing burden
Язык: Английский
Процитировано
1
Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 200, С. 104407 - 104407
Опубликована: Июнь 2, 2024
Язык: Английский
Процитировано
0